Anti-Tau For Alzheimer's In The Dock After Semorinemab Fail
AC Immune And Roche Candidate Latest In A Long Line Of Misses
Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.
